Cargando…

Correlation of Peripheral Blood Parameters and Immune-Related Adverse Events with the Efficacy of Immune Checkpoint Inhibitors

OBJECTIVE: We aimed to retrospectively analyze the predictors of immune checkpoint inhibitors (ICIs)-efficacy in patients with advanced pancancer who were treated with various ICIs in the real world and focused on the correlation between ICIs-efficacy and immune-related adverse events (irAEs). METHO...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bai, Rilan, Li, Lingyu, Chen, Xiao, Chen, Naifei, Song, Wei, Zhang, Yongfei, Lv, Zheng, Han, Fujun, Zhao, Yuguang, Li, Wei, Cui, Jiuwei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8292079/ https://www.ncbi.nlm.nih.gov/pubmed/34335763 http://dx.doi.org/10.1155/2021/9935076

Ejemplares similares

Analysis of characteristics and predictive factors of immune checkpoint inhibitor-related adverse events
por: Bai, Rilan, et al.
Publicado: (2021)

Predictive biomarkers for cancer immunotherapy with immune checkpoint inhibitors
por: Bai, Rilan, et al.
Publicado: (2020)

Neoadjuvant and Adjuvant Immunotherapy: Opening New Horizons for Patients With Early-Stage Non-small Cell Lung Cancer
por: Bai, Rilan, et al.
Publicado: (2020)

Novel Frontiers of Treatment for Advanced Gastric or Gastroesophageal Junction Cancer (GC/GEJC): Will Immunotherapy Be a Future Direction?
por: Bai, Rilan, et al.
Publicado: (2020)

Favorable Immune Microenvironment in Patients with EGFR and MAPK Co-Mutations
por: Yang, Wang, et al.
Publicado: (2020)

Mechanisms of Cancer Resistance to Immunotherapy
por: Bai, Rilan, et al.
Publicado: (2020)

Advances in novel molecular typing and precise treatment strategies for small cell lung cancer
por: Bai, Rilan, et al.
Publicado: (2021)

Potential new applications of immunotherapy for neuroendocrine neoplasms: immune landscape, current status and future perspectives
por: Bai, Rilan, et al.
Publicado: (2022)

Targeted therapy combined with immunotherapy in patients with breast infiltrating ductal carcinoma with axillary lymph node metastasis of metaplastic SCC
por: Bai, Rilan, et al.
Publicado: (2022)

Efficacy of second-line treatments for patients with advanced human epidermal growth factor receptor 2 positive breast cancer after trastuzumab-based treatment: a systematic review and bayesian network analysis
por: Chen, Fei, et al.
Publicado: (2021)

Single Nucleotide Polymorphisms in HOTAIR Are Related to Breast Cancer Risk and Prognosis in the Northeastern Chinese Population
por: Lv, Zheng, et al.
Publicado: (2021)

Peripheral nervous system adverse events associated with immune checkpoint inhibitors
por: Rossi, Simone, et al.
Publicado: (2023)

Immune-related adverse events of immune checkpoint inhibitors: a review
por: Yin, Qinan, et al.
Publicado: (2023)

Ophthalmic immune-related adverse events associated with immune checkpoint inhibitors
por: Gan, Linyang, et al.
Publicado: (2023)

Burgeoning Exploration of the Role of Natural Killer Cells in Anti-PD-1/PD-L1 Therapy
por: Bai, Rilan, et al.
Publicado: (2022)

Development of Immunotherapy Strategies Targeting Tumor Microenvironment Is Fiercely Ongoing
por: Bai, Rilan, et al.
Publicado: (2022)

Bibliometric analysis of rheumatic immune related adverse events associated with immune checkpoint inhibitors
por: Zeng, Li, et al.
Publicado: (2023)

Ocular adverse events with immune checkpoint inhibitors
por: Fang, Tony, et al.
Publicado: (2019)

Mucocutaneous adverse events to immune checkpoint inhibitors
por: Muhaj, Fiorinda, et al.
Publicado: (2023)

Unexpected Adverse Events of Immune Checkpoint Inhibitors
por: Shalata, Walid, et al.
Publicado: (2023)

Immune Checkpoint Inhibitors and Immune-Related Adverse Renal Events
por: Herrmann, Sandra M., et al.
Publicado: (2020)

Meta‐analysis of immune‐related adverse events of immune checkpoint inhibitor therapy in cancer patients
por: Song, Peng, et al.
Publicado: (2020)

Ocular Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors in Lung Cancer
por: Zhou, Lin, et al.
Publicado: (2021)

Landscape of immune checkpoint inhibitor-related adverse events in Chinese population
por: Li, Li, et al.
Publicado: (2020)

Peripheral lymphocyte fluctuation as an indicator of severe immune‐related adverse events in patients treated with immune checkpoint inhibitors
por: Haraguchi, Masafumi, et al.
Publicado: (2023)

The biomarkers related to immune related adverse events caused by immune checkpoint inhibitors
por: Jia, Xiao-Hui, et al.
Publicado: (2020)

Precision Detection Technology: Equipping Precision Oncology with Wings
por: Bai, Rilan, et al.
Publicado: (2020)

Management of immune checkpoint inhibitor‐related dermatologic adverse events
por: Si, Xiaoyan, et al.
Publicado: (2019)

Management of immune checkpoint inhibitor‐related rheumatic adverse events
por: Zhou, Jiaxin, et al.
Publicado: (2019)

Clinical recommendations on diagnosis and treatment of immune checkpoint inhibitor‐induced renal immune‐related adverse events
por: Zheng, Ke, et al.
Publicado: (2020)

Rheumatic immune‐related adverse events induced by immune checkpoint inhibitors
por: Zhong, Hui, et al.
Publicado: (2020)

Cardiac Adverse Events Related to Immune Checkpoint Inhibitors
por: Gujral, Dorothy M., et al.
Publicado: (2020)

Precision targeted therapy for EGFR mutation‐positive NSCLC: Dilemmas and coping strategies
por: Meng, Ying, et al.
Publicado: (2023)

Challenges of evaluating immunotherapy efficacy in solid tumors
por: Bai, Rilan, et al.
Publicado: (2019)

Epidermal growth factor receptor compound and concomitant mutations: advances in precision treatment strategies
por: Li, Wenqian, et al.
Publicado: (2023)

Treatment- and immune-related adverse events of immune checkpoint inhibitors in advanced lung cancer
por: Shao, Jun, et al.
Publicado: (2020)

Rechallenge of immune checkpoint inhibitors in a case with adverse events inducing myasthenia gravis
por: Gao, Wen, et al.
Publicado: (2022)

Nerves in the Tumor Microenvironment: Origin and Effects
por: Wang, Wenjun, et al.
Publicado: (2020)

Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors
por: Das, Satya, et al.
Publicado: (2019)

Equibalancing immune‐related adverse events and anticancer activity of immune checkpoint inhibitors
por: Seeruttun, Sharvesh Raj
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_npvdve6vjibcpa24boeanqb4ts